CANDEL THERAPEUTICS INC. - COMMON STOCK

8,6700

10-февраля-25 16:45:00

15 мин. задержка

Акции

+0,0100

+0,12%

Сегодняшний диапазон

8,4550 - 8,8180

ISIN

N/A

Источник

NASDAQ

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

11 апр 2024 09:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

09 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

04 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

28 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

28 мар 2024 08:05:47 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

13 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

05 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

12 дек 2023 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

28 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

09 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

04 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

03 ноя 2023 12:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

18 окт 2023 11:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

27 сен 2023 09:40:53 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

26 сен 2023 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

10 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

02 авг 2023 08:00:29 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

13 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.